articleTop 1% cited

A WORLDWIDE, PHASE III, RANDOMIZED, CONTROLLED, SAFETY AND EFFICACY STUDY OF A SIROLIMUS/CYCLOSPORINE REGIMEN FOR PREVENTION OF ACUTE REJECTION IN RECIPIENTS OF PRIMARY MISMATCHED RENAL ALLOGRAFTS

Transplantation · 2001 · Vol. 71(2) · pp. 271–280

Allan S. MacDonald✉(Dalhousie University)

Abstract

The addition of either 2 mg/day sirolimus or 5 mg/day sirolimus to CsA/corticosteroid therapy significantly reduces the incidence of acute rejection episodes in primary mismatched renal allograft recipients, without an increase in immunosuppressant-related side effects, including infections and malignancy, at 6 months and at 1 year after transplantation.

Renal Transplantation Outcomes and Treatments Organ Transplantation Techniques and Outcomes Pharmacological Effects and Toxicity StudiesMedicineSirolimusClinical endpointRegimenTransplantationUrologyKidney transplantationSurgeryPlaceboAlemtuzumab

MeSH terms

Acute DiseaseAdolescentAdultCadaverDouble-Blind MethodFemaleGraft RejectionHistocompatibility TestingHumansMaleMiddle AgedKidney TransplantationCyclosporineSirolimus

Citations

620

FWCI

34.11

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients